Conference coverage
St. Jude CEO: Medtronic’s renal denervation miss doesn’t dampen our spirits
Simple test could save 2,000 newborns per year, so why don’t more hospitals do it?
Thousands of newborn babies die or suffer serious illness each year for want of a cheap, readily available medical device to test for congenital heart disease, according to neonatal health experts.
Nearly 30 device makers pledge to share data to make patients safer
The growing Patients Safety Movement has more than doubled its commitments from medtech companies over the course of a single year, with nearly 30 companies promising so far to make the data gathered by their devices available to anyone interested in improving patient care.
Women in the corner office: Lessons in leadership from Yahoo CEO Marissa Mayer
Good leadership is about stripping away the self-gratifying illusions and driving the company toward a goal, superstar technology industry CEO Marissa Mayer told an audience of tens of thousands at last night’s Dreamforce conference in San Francisco.
Take renal stenting off the front lines, researchers say
The highly anticipated results from the CORAL clinical trial wasn’t great news for renal stents, as researchers reported that renal-artery stenting offered "no benefits" over drugs alone in treating patients with atherosclerotic renal-artery stenosis and elevated blood pressure, chronic kidney disease, or both.
Medtronic’s next-gen pacemakers help slow heart disease, study says
Deflating the hype: Are we setting renal denervation up for disappointment?
Renal denervation is still in its youth, but the limited clinical trials and lack of substantial confirmation hasn’t curbed much of the hype for the technology as a means of treating patients with resistant hypertension.
From Moneyball to medtech: Author Michael Lewis on the mindset of a disruptor
There’s no formula for disruptive innovation, but there are certain traits that seem to crop up time and again in the individuals who drive it.